Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -25.82
- Piotroski Score 4.00
- Grade Neutral
- Symbol (ACER)
- Company Acer Therapeutics Inc.
- Price $0.90
- Changes Percentage (0%)
- Change $0.9
- Day Low $0.90
- Day High $0.90
- Year High $0.90
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/19/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.93
- Trailing P/E Ratio -0.3420207253886
- Forward P/E Ratio -0.3420207253886
- P/E Growth -0.3420207253886
- Net Income $-27,860,371
Income Statement
Quarterly
Annual
Latest News of ACER
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Myles Turner has 30 points and 11 rebounds, the Pacers beat the Mavericks 134-127
Myles Turner led the Indiana Pacers to a 134-127 victory over the Dallas Mavericks with 30 points and 11 rebounds. Tyrese Haliburton added 25 points and 12 assists. Pacers played without Isaiah Jackso...
By AP NEWS | 18 hours ago -
Achilles Tear For Isaiah Jackson May Force Indiana Pacers To Make Move
Indiana Pacers' reserve center Isaiah Jackson suffered a torn Achilles tendon, likely sidelining him for the season. This injury disrupts the team's rotation and leaves them with limited options at ce...
By Forbes | 2 days ago -
Zion Williamson has 34 points and 10 assists to lead Pelicans past Pacers, 125-118
Zion Williamson's 34 points lead Pelicans to a 125-118 win over Pacers. Brandon Ingram adds 26 points. New Orleans ends a three-game losing streak. Injuries impact Pacers' performance. Pelicans capita...
By AP NEWS | 3 days ago
